博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06955 博安生物

已收盘 08-20 16:09:07

4.300

+0.130

+3.12%

最高4.510	最低4.185	成交量946.62万
今开4.295	昨收4.170	日振幅7.79%
总市值26.75亿	流通市值26.76亿	总股本6.22亿
成交额4,116万	换手率1.52%	流通股本6.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06955","market":"HK","secType":"STK","nameCN":"博安生物","latestPrice":4.3,"timestamp":1787213347867,"preClose":4.17,"halted":0,"volume":9466200,"delay":0,"changeRate":0.031175059952038345,"floatShares":622333694,"shares":622000000,"eps":0.1593747378597369,"marketStatus":"已收盘","change":0.13,"latestTime":"08-20 16:09:07","open":4.295,"high":4.51,"low":4.185,"amount":41156124,"amplitude":0.077938,"askPrice":4.3,"askSize":48000,"bidPrice":4.25,"bidSize":28400,"shortable":3,"etf":0,"ttmEps":0.06575814078077324,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"listingDate":1672329600000,"exchange":"SEHK","adjPreClose":4.17,"openAndCloseTimeList":[[1787189400000,1787198400000],[1787202000000,1787212800000]],"volumeRatio":2.882196,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06955","defaultTab":"news","newsList":[{"id":"2659140570","title":"博安生物(06955.HK)拟8月27日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2659140570","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659140570?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:47","pubTimestamp":1786718824,"startTime":"0","endTime":"0","summary":"格隆汇8月14日丨博安生物(06955.HK)公告，将于2026年8月27日(星期四)举行董事会会议，藉以(其中包括)批准公司截至2026年6月30日止中期业绩及其发布，并考虑派发中期股息(如有)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260814/32335982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147909","title":"博安生物(06955)：BA1302 (CD228 ADC)完成中国Ia期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659147909?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:22","pubTimestamp":1786717377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，公司自主研发的靶向CD228的创新抗体偶联药物BA1302已完成中国I期临床研究单药剂量递增阶段(Ia期)。研究结果显示，BA1302在经多线治疗后疾病仍进展的多种晚期实体瘤患者中展现出良好的抗肿瘤活性，整体安全耐受性良好。据公司所知，BA1302是目前全球唯一处于临床阶段的靶向CD228 ADC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NETL","BK4231","06955","ADC","BK1161","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154197598","title":"博安生物（06955）发布盈利预警 预计2026年上半年亏损79至89百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154197598","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154197598?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:21","pubTimestamp":1786717306,"startTime":"0","endTime":"0","summary":"博安生物8月14日公告称，根据截至2026年6月30日止六个月的未审核运营数据及董事会初步评估，公司预计期内录得归属于公司权益持有人净亏损约79百万元至89百万元。董事会指出，由盈转亏的主要原因是研发投入显著增加。公司目前仍在落实中期业绩，相关数据未经核数师及审计委员会审核确认。博安生物计划于2026年8月27日公布2026年上半年中期业绩。公司提醒股东及潜在投资者在买卖公司股份时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182085940","title":"博安生物（06955）将于8月27日召开董事会审议2026年中期业绩及派息事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1182085940","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182085940?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:21","pubTimestamp":1786717294,"startTime":"0","endTime":"0","summary":"博安生物（06955）8月14日在港交所公告，公司董事会将于2026年8月27日（星期四）召开会议，拟审议并批准公司截至2026年6月30日止六个月的中期业绩及其发布事宜，同时考虑派发中期股息（如有）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131549479","title":"博安生物（06955）：全球唯一临床阶段CD228靶向ADC BA1302完成中国Ia期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1131549479","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131549479?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:21","pubTimestamp":1786717260,"startTime":"0","endTime":"0","summary":"2026年8月14日，山東博安生物技術股份有限公司发布自愿性公告称，公司自主研发的靶向CD228抗体偶联药物BA1302已完成中国I期临床研究单药剂量递增阶段（Ia期）。这是目前全球唯一进入临床阶段的CD228 ADC。本次Ia期为多中心、开放标签研究，旨在评估BA1302单药治疗晚期恶性实体瘤患者的安全性、耐受性、药代动力学特征、免疫原性及初步抗肿瘤疗效。公司表示，初步数据支持继续加快BA1302的全球开发进程，探索其在更多适应症中的临床应用价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659314795","title":"博安生物(06955)发盈警 预期中期股东应占净亏损约7900万元至8900万元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2659314795","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659314795?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:18","pubTimestamp":1786717111,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，预期集团于截至2026年6月30日止6个月(报告期)将取得公司权益拥有人应占净亏损约人民币7900万元至人民币8900万元，而截至2025年6月30日止6个月则取得公司权益拥有人应占净溢利约人民币2100万元。因此，该等项目临床试验开支及研发开支于报告期内显著增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"博安生物(06955)发盈警 预期中期股东应占净亏损约7900万元至8900万元 同比盈转亏","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191370744","title":"博安生物预计中期业绩转亏，主因研发投入大幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1191370744","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191370744?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:17","pubTimestamp":1786717069,"startTime":"0","endTime":"0","summary":"山东博安生物技术股份有限公司（证券简称：博安生物，股票代码：06955）近日发布公告，预计其上半年业绩将由盈转亏。这一预期变化的核心原因，是该公司在研发领域的支出显著攀升。研发投入的大幅增加，直接导致了公司整体财务状况的转向。具体而言，博安生物正在积极布局多个创新药物管线，这些项目的推进需要大量资金支持。因此，尽管公司其他业务可能保持稳定，但研发费用的膨胀已足以将整体盈利表现拖入亏损区间。这一动向也反映出生物科技行业普遍面临的“高投入、长周期”的典型特征，即前期研发阶段的巨额支出往往会对短期利润构成压力，以便为未来的产品上市和商业化奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969253","title":"港股异动 | 博安生物(06955.HK)午前涨超3% 近日阿柏西普眼内注射溶液在巴西提交上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969253","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969253?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:56","pubTimestamp":1786420605,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144440243","title":"博安生物7月无新增发行或回购，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1144440243","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144440243?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:39","pubTimestamp":1786005548,"startTime":"0","endTime":"0","summary":"山东博安生物技术股份有限公司于2026年8月6日发布了截至2026年7月31日的最新股份变动月报。报告显示，公司在7月期间未进行新增发行、购回或注销股份等活动，股本规模与上月底保持一致。公司进一步声明，月内所有与证券发行及库藏股份相关的事项均已获得董事会正式批准并遵守了香港联交所《上市规则》及所有适用法律法规。根据本次月报，博安生物7月股本维持不变，整体运营稳健。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657544690","title":"博安生物：阿柏西普眼内注射溶液已申请在巴西上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657544690","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657544690?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:11","pubTimestamp":1785931860,"startTime":"0","endTime":"0","summary":"8月5日，博安生物（06955）发布公告，公司的阿柏西普眼内注射溶液上市许可申请已在巴西国家卫生监督管理总局完成提交，拟用于治疗成人新生血管（湿性）年龄相关性黄斑变性和糖尿病性黄斑水肿。公告提到，阿柏西普眼内注射溶液是艾力雅?的生物类似药，已于2025年11月在中国获批上市。作为公司践行全球开发策略的重点品种之一，阿柏西普眼内注射溶液的海外布局正在加速拓展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608053832759832.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608053832759832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06955","159100","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175929146","title":"博安生物提交BA9101巴西上市许可申请 目标nAMD及DME市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1175929146","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175929146?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:06","pubTimestamp":1785931563,"startTime":"0","endTime":"0","summary":"山東博安生物技術股份有限公司8月5日发布自愿性公告称，公司阿柏西普眼内注射溶液BA9101的上市许可申请已向巴西国家卫生监督管理局完成提交，用于治疗成人新生血管（湿性）年龄相关性黄斑变性和糖尿病性黄斑水肿。\\n\\n公司表示，此次向巴西提交上市许可申请是BA9101全球布局的重要一步，将与合作伙伴推动产品在更多国家的申报及上市。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2651965641","title":"港股异动 | 博安生物(06955.HK)涨超4% 近日BA1203临床试验申请获CDE受理 将成为公司下一代IO治疗重要布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2651965641","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651965641?lang=zh_cn&edition=full","pubTime":"2026-07-13 14:37","pubTimestamp":1783924677,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649957291","title":"博安生物：新药BA1203临床试验申请获CDE受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2649957291","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649957291?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:52","pubTimestamp":1783486320,"startTime":"0","endTime":"0","summary":"7月8日，博安生物（06955）发布公告，公司在研PD-1/IL-2抗体细胞因子前药BA1203的新药临床试验申请(IND)已获得中国国家药品监督管理局药品审评中心（CDE）受理。BA1203为本公司自主开发的新一代肿瘤免疫候选药物，拟开发用于多种实体瘤的治疗。据公司所知，该在研药物将成为中国首个进入临床的保留α亚基结合活性的遮蔽型PD-1/IL-2抗体细胞因子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798163888.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798163888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BMED","LU1223083913.SGD","GDXJ","SIL","LU1223082519.USD","IBBQ","SGDM","XME","BK4017","BK1161","LU1223082196.USD","06955","CDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649957317","title":"博安生物(06955.HK)：BA1203(遮蔽型PD-1/IL-2)临床试验申请获CDE受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2649957317","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649957317?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:22","pubTimestamp":1783484539,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191664128","title":"博安生物（06955）PD-1/IL-2候选药物BA1203获CDE受理临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1191664128","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191664128?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:05","pubTimestamp":1783483529,"startTime":"0","endTime":"0","summary":"2026年7月8日，博安生物公告称，公司自主研发的新一代肿瘤免疫候选药物BA1203的临床试验申请已获国家药品监督管理局药品审评中心受理。该产品为保留α亚基结合活性的遮蔽型PD-1/IL-2抗体细胞因子前药，用于多种实体瘤治疗。据公司披露，BA1203有望成为中国首个进入临床阶段的同类品种。公司表示，将加快推进BA1203的临床开发，并进一步探索单药及联合用药路径，以验证其潜在的差异化治疗价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649954218","title":"创新药板块走低 科伦博泰生物(06990)跌7.67% 当前板块仍处估值修复行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2649954218","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649954218?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:08","pubTimestamp":1783480087,"startTime":"0","endTime":"0","summary":"有研究指，创新药板块年内曾两轮短期反弹，本轮行情依托政策组合、高含金量海外交易、机构持续加仓三大不同支撑，但机构表示当前仅为估值修复行情，基本面全面反转仍需中期、三季度财报验证，后续走势重点跟踪企业盈利兑现与CGT正式政策落地进度。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985359","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LU0979878070.USD","06855","LU1880383366.USD","02359","KURE","LU0819121731.USD","IE00B0JY6N72.USD","CZA","LU3063872942.SGD","01477","SG9999014674.SGD","06955","LU0417516571.SGD","LU1046422090.SGD","02268","BK1191","02269","LU0052750758.USD","LU0516422440.USD","00460","BK1583","BK1141","REVS","159992","LU0320764599.SGD","LU0326950275.SGD","BK1521","06990","09926","LU0516423091.SGD","LU2476274308.USD","01672","02186","LU0456846285.SGD","06978","LU0140636845.USD","LU0572944931.SGD","LU0348784397.USD","SG9999002463.SGD","LU0051755006.USD","BK1600","LU0348783233.USD","BK1515","01952","LU0588546209.SGD","LU0196878994.USD","01530","MEDX","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142343990","title":"博安生物更新6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1142343990","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142343990?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:52","pubTimestamp":1783327975,"startTime":"0","endTime":"0","summary":"山东博安生物技术股份有限公司于2026年7月6日发布截至2026年6月30日的股份变动月报表。公告显示，报告期内公司注册股本为人民币622,333,694元，对应已发行的H股共622,333,694股，与上月底一致，未发生新增发行、购回、注销或库藏股变动。根据月报表内容，普通股的已发行股份数量在本月保持不变，H股库存股份数量亦无变化，期末结存仍为622,333,694股。期权与股权激励计划、购回与注销方面未出现新增信息，公司股本结构保持稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181629848","title":"博安生物（06955）BA1106联合BA1104治疗NSCLC获CDE批准开展Ⅱ期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1181629848","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181629848?lang=zh_cn&edition=full","pubTime":"2026-07-02 19:20","pubTimestamp":1782991249,"startTime":"0","endTime":"0","summary":"2026年7月2日，博安生物公告称，其自主开发的创新抗体BA1106联合公司自有PD-1抑制剂BA1104用于非小细胞肺癌一线及二线治疗的Ⅱ期临床试验申请已获国家药品监督管理局药品审评中心正式批准。本次获批的Ⅱ期临床试验为多中心、单臂、开放标签设计，将在驱动基因阴性的NSCLC受试者中系统评估BA1106联合BA1104的疗效、安全性及药代动力学特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648044885","title":"博安生物：BA1106联合BA1104治疗NSCLC II期临床试验获CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2648044885","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648044885?lang=zh_cn&edition=full","pubTime":"2026-07-02 19:15","pubTimestamp":1782990900,"startTime":"0","endTime":"0","summary":"南财智讯7月2日电，博安生物（06955.HK）发布自愿公告，公司自主研发的创新抗体BA1106（抗CD25单抗）联合自有PD-1抑制剂BA1104（纳武利尤单抗）用于非小细胞肺癌（NSCLC）一线及二线治疗的II期临床试验申请，已正式获得国家药品监督管理局药品审评中心（CDE）批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607023792074551.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607023792074551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CDE","LU1223082196.USD","BK4017","BK1161","LU1223083913.SGD","LU1223082519.USD","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648504300","title":"博安生物(06955.HK)：BA1106联合BA1104治疗非小细胞肺癌的 Ⅱ期临床试验申请获CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2648504300","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648504300?lang=zh_cn&edition=full","pubTime":"2026-07-02 19:11","pubTimestamp":1782990711,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.boan-bio.com","stockEarnings":[{"period":"1week","weight":-0.0984},{"period":"1month","weight":-0.1775},{"period":"3month","weight":-0.3119},{"period":"6month","weight":-0.4513},{"period":"1year","weight":-0.7403},{"period":"ytd","weight":-0.5117}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.0348},{"period":"1year","weight":0.0148},{"period":"ytd","weight":-0.0053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"山东博安生物技术股份有限公司是一家主要从事生物制药的中国公司。该公司主要从事治疗用抗体的开发、生产和商业化，专注于肿瘤学、代谢学、自身免疫学和眼科等治疗领域。该公司主要拥有三个技术平台：全人抗体转基因小鼠及噬菌体展示技术平台、双特异T-cell Engager技术平台、抗体药物偶联（ADC）技术平台。该公司主要在中国国内市场和海外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.161165},{"month":2,"riseRate":0.5,"avgChangeRate":-0.012143},{"month":3,"riseRate":0.25,"avgChangeRate":-0.003652},{"month":4,"riseRate":0.75,"avgChangeRate":0.065191},{"month":5,"riseRate":0.25,"avgChangeRate":-0.057252},{"month":6,"riseRate":0.25,"avgChangeRate":-0.04333},{"month":7,"riseRate":0.75,"avgChangeRate":0.130145},{"month":8,"riseRate":0,"avgChangeRate":-0.101027},{"month":9,"riseRate":0.666667,"avgChangeRate":0.038827},{"month":10,"riseRate":0,"avgChangeRate":-0.109251},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.02386},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.011932}],"exchange":"SEHK","name":"博安生物","nameEN":"BOAN BIOTECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博安生物(06955)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博安生物,06955,博安生物股票,博安生物股票老虎,博安生物股票老虎国际,博安生物行情,博安生物股票行情,博安生物股价,博安生物股市,博安生物股票价格,博安生物股票交易,博安生物股票购买,博安生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博安生物(06955)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}